# Cardioxyl Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cardioxyl-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Chapel Hill, US
- Website: www.cardioxyl.com
- Total disclosed funding: $61M
- Latest round: Series B (Nov 5, 2012)
- Investors on record: 4

## About

Cardioxyl Pharmaceuticals focuses on developing innovative therapeutic solutions for cardiovascular diseases, emphasizing transformative treatments and advanced drug formulations.Founded in 2005 and headquartered in Chapel Hill, US, Cardioxyl Pharmaceuticals specializes in cardiovascular therapeutics. In November 2015, Bristol-Myers Squibb acquired Cardioxyl Pharmaceuticals. The company has successfully completed six deals, with its latest funding round being a Series B of USD 28.050 mn led by OrbiMed Advisors, bringing the total amount raised to USD 28.050 mn and valuing the company at USD 43.656 mn.Cardioxyl Pharmaceuticals specializes in creating advanced therapeutic solutions aimed at treating cardiovascular conditions. The company’s key product offerings include innovative drug formulations designed to improve heart health and patient outcomes. Its solutions cater to healthcare providers and institutions, addressing critical needs in cardiac care. The products have been utilized in various markets, including North America, Europe, and Asia-Pacific, demonstrating the company's commitment to serving a diverse range of healthcare clients.Cardioxyl Pharmaceuticals operates on a revenue model centered around the sale of its pharmaceutical products, providing access to its innovative therapies through various partnerships with healthcare systems and providers. This model enables consistent revenue streams and promotes long-term relationships with clients. The company’s revenue is bolstered through strategic collaborations, enhancing its market presence and operational stability.Cardioxyl Pharmaceuticals aims to expand its portfolio with new cardiovascular therapeutic products, with several under development expected to launch by late 2026. The company plans to extend its market reach into Europe and Asia, targeting these regions for expansion by 2027. Recent funding from the Series B round will support these initiatives, facilitating R&D activities and enhancing operational capabilities to meet growing market demands.

## Funding rounds

- Series B, Nov 5, 2012, $28M — Aurora Funds, New Enterprise Associates, OrbiMed Advisors, OUP (Osage University Partners)
- Series A, Aug 2, 2010, $15M — Aurora Funds, New Enterprise Associates
- Series A, Aug 18, 2009, $9M — Aurora Funds, New Enterprise Associates
- Series A, Oct 1, 2008, $6M — Aurora Funds
- Series A, Dec 6, 2006, $3.2M — Aurora Funds, New Enterprise Associates

## Investors

- Aurora Funds (https://capitalatlas.ai/funds/aurora-funds) — Series A, Series B
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series B